A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Study sponsor: Verastem, Inc. · VSTM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-10-15Estimated
Enrollment · participants270Estimated
Source updated2026-11-02Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.